title: Structure-based drug design: combinatorial chemistry and molecular modeling.
abstract: Drug discovery efforts are shifting to include the rapid synthetic procedures of combinatorial chemistry and the elegance of rational library design. The wealth of computational methods which explore both the receptor structure and the ultimate pharmacophore complementarity, provide novel avenues for chemists to discover new lead compounds or design virtual libraries for screening prior to the synthetic stage. This mini-review provides an overview of a few current methodologies of library generation, highlighting docking procedures which have utility in both the discovery and optimization stages of drug development. Three specific examples of different approaches to the use of docking are provided. These describe the development of inhibitors to the human A3 adenosine receptor and HIV-1 protease, and the evaluation of the activity of novel inhibitors of the redox regulator protein, human thioredoxin.
authors.affiliation: ProlX Pharmaceuticals, Inc., Pittsburgh, PA, USA. Lynn.Kirkpatrick@uregina.ca
authors.forename: D L
authors.initials: DL
authors.lastname: Kirkpatrick
authors.forename: S
authors.initials: S
authors.lastname: Watson
authors.forename: S
authors.initials: S
authors.lastname: Ulhaq
mesh_terms: D002625:Chemistry, Organic / Q000379:methods*; D016208:Databases, Factual; D015195:Drug Design; D017320:HIV Protease Inhibitors / Q000138:chemical synthesis; D006801:Humans; D008958:Models, Molecular; D058915:Purinergic P1 Receptor Antagonists; D043684:Receptor, Adenosine A3; D013329:Structure-Activity Relationship
chemical_list: D017320:HIV Protease Inhibitors; D058915:Purinergic P1 Receptor Antagonists; D043684:Receptor, Adenosine A3